Effect of Darbepoetin Alfa on Renal Anemia in Japanese Hemodialysis Patients

Abstract

Introduction:

A long-acting erythropoiesis-stimulating agent named “darbepoetin alfa” (CAS 11096-26-7) was recently developed. Though it is already in use worldwide, especially in western countries, its efficacy and safety for Asian patients have not been well evaluated yet. The purpose of this study was to evaluate the efficacy and safety of short-term darbepoetin alfa administration for Japanese hemodialysis patients.

Methods:

Patients who had undergone maintenance hemodialysis were enrolled in this study. The erythropoiesis-stimulating agent was switched from epoetin alfa (CAS 113427-24-0) to darbepoetin alfa so as to control the hemoglobin (Hgb) value between 10 and 12 g/dl. The initial conversion ratio was made according to the manufacturer’s recommendations. The factors relevant to the responsiveness to erythropoiesis were analyzed.

Results:

One hundred and fifty-nine patients with a mean age of 67.6 years were enrolled. Two months after switching to darbepoetin alfa, the Hgb value had increased significantly (10.3 ± 1.2 to 10.6 ± 1.4 g/dl). Only iron supplementation correlated positively with the change of Hgb. In addition, 14.3% of patients had excess Hgb (Hgb > 12 g/dl) at the end of the study period, but only 5.6% patients at the run-in. Serious cardiovascular disease did not occur during the study period; however, the mean systolic blood pressure at the start of hemodialysis increased significantly and there was no correlation between the change of Hgb value and blood pressure.

Conclusion:

Darbepoetin alfa increases the Hgb value effectively in Japanese hemodialysis patients. Although no serious adverse events were apparent in our short-term analysis, the incidence of hypertension and excessive increase of the Hgb value must be noted.

Key words

CAS 11096-26-7 - Darbepoetin alfa - Erythropoiesis-stimulating agent - Japanese hemodialysis patients - Renal anemia

• References

• 1 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108: 2154-69
• 2 Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997; 77: 176-85
• 3 Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66: 753-60
• 4 Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D et al. The interaction between heart failure, renal failure and anemia – the cardio-renal anemia syndrome. Blood Purif. 2004; 22: 277-84
• 5 Gurm HS, Lincoff AM, Kleiman NS, Kereiakes DJ, Tcheng JE, Aronow HD et al. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. Am J Cardiol. 2004; 94: 30-4
• 6 Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003; 64: 610-5
• 7 Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001; 16 (Suppl 3) 14-21
• 8 Fukuhara S, Akizawa T, Morita S, Koshikawa S. Quality of Life Improvements in Dialysis Patients Receiving Darbepoetin Alfa. Ther Apher Dial. 2008; 12: 72-7
• 9 Akizawa T, Koshikawa S, Iwasaki M. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. Ther Apher Dial. 2007; 11: 220-6
• 10 Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M et al. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004; 8: 443-59
• 11 Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007; 11: 411-41
• 12 Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 2003; 18: 362-9
• 13 Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-84
• 14 Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-98
• 15 Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-90
• 16 Radermacher J, Koch KM. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Clin Nephrol. 1995; 44 (Suppl 1) S56-60
• 17 Nowicki M. Erythropoietin and hypertension. J Hum Hypertens. 1995; 9: 81-8
• 18 Yamakado M, Umezu M, Nagano M, Tagawa H. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med. 1991; 14: 623-9
• 19 Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant. 1995; 10 (Suppl 2) 74-9
• 20 Ishimitsu T, Tsukada H, Ogawa Y, Numabe A, Yagi S. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med. 1993; 94: 401-6